CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 58 enrolled
Drug / intervention
armodafinil (Nuvigil) +1 moredrug
Likely dose
armodafinil (Nuvigil) 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00373672
NCT00373672Phase 4Completed
CompareCT.gov

Effect of Addition of Modafinil on the Tolerability and Efficacy for Cognition of Atypical Antipsychotic Drugs in Patients With Schizophrenia or Schizoaffective Disorder

Northwestern University·interventional·Posted Sep 8, 2006·Updated Aug 5, 2025

In Brief

A Phase 4 clinical trial evaluating armodafinil (Nuvigil) and placebo for Schizophrenia and Schizoaffective Disorder. Completed, enrolled 58 participants across 1 site.

Detailed Summary

This is a six week, double blind,placebo controlled study for patients with schizophrenia or schizoaffective disorder treated with an atypical antipsychotic for at least two months. Subjects will be randomized to take armodafinil (Nuvigil) or placebo along with their current antipsychotic and tested at baseline and week 6 for differences in memory, attention and problem-solving ability. Changes in weight during the six week study will also be tracked.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia, Schizoaffective Disorder
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression, Cephalon

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 8, 2006
Enrollment StartAug 1, 2006
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 19.8 years ago

Interventions

armodafinil (Nuvigil)drug

armodafinil (Nuvigil)150 mg qd

placebodrug

identical in appearance to active comparator